Cost-Effectiveness Of Beta Interferon

EDM number 957 in 1999-00, proposed by Paul Burstow on 11/07/2000.

That this House notes that new research has demonstrated that the cost of beta interferon should be calculated on the assumption that its benefits can be long-term and that the cost of the drug is outweighted by the cost to society of caring for a patient disabled by MS; and calls on the National Institute for Clinical Excellence to examine the findings reported in the journal Pharmaco Economics and to take evidence from people with MS.

This motion has been signed by a total of 37 MPs.